Clinical and Translational Evaluation of a SAMe-5-HTP-Hypericum Compound Nutritional Supplement for Emotional Support and Joint Care

Abstract

We evaluated a disclosed SAMe-5-HTP-Hypericum compound nutritional supplement developed for dual-domain emotional support and joint care, and we aligned the disclosed formulation data with published human clinical evidence for the principal active ingredients. The formulation combines S-adenosyl-L-methionine (SAMe), 5-hydroxytryptophan (5-HTP), and St. John's wort extract with sodium chondroitin sulfate, sodium hyaluronate, vitamin B6, vitamin E, and phosphatidylserine. We selected the upper-limit formulation as the lead candidate because it showed the best disclosed performance across both emotional-support and joint-care models. In the forced-swimming model, the lead formulation reduced immobility time to 108.7 ± 11.2 s versus 142.8 ± 14.6 s for the comparator formulation without the joint-care synergists. In the rat osteoarthritis model, it increased cartilage matrix synthesis to 1089 ± 91 cpm/mg and synovial fluid viscosity to 11.2 ± 1.0 mPa·s, outperforming the comparator values of 721 ± 68 cpm/mg and 7.2 ± 0.7 mPa·s. Published human evidence showed that SAMe monotherapy was superior to placebo for depressive symptoms in a 2024 meta-analysis (23 trials, N = 2183; SMD = -0.58), St. John's wort was superior to placebo for mild-to-moderate depression and not significantly different from antidepressants in effectiveness while showing fewer adverse events, 5-HTP showed a pooled remission rate of 0.65 but with marked methodological weakness, and chondroitin provided a small-to-moderate short-term benefit in osteoarthritis. Taken together, these findings support a clinically plausible and mechanistically coherent dual-domain supplement architecture. Direct randomized clinical trials of the finished composition remain necessary before therapeutic superiority claims can be finalized.